Steven B. Kanner
Net Worth

Last updated:

What is Steven B. Kanner net worth?

The estimated net worth of Dr. Steven B. Kanner is at least $3,030,989 as of 6 Feb 2024. He owns shares worth $543,706 as insider, has earned $485,243 from insider trading and has received compensation worth at least $2,002,040 in Caribou Biosciences, Inc..

What is the salary of Steven B. Kanner?

Dr. Steven B. Kanner salary is $500,510 per year as Chief Scientific Officer in Caribou Biosciences, Inc..

How old is Steven B. Kanner?

Dr. Steven B. Kanner is 66 years old, born in 1959.

What stocks does Steven B. Kanner currently own?

As insider, Dr. Steven B. Kanner owns shares in one company:

Company Title Shares Price per share Total value
Caribou Biosciences, Inc. (CRBU) Chief Scientific Officer 302,059 $1.8 $543,706

What does Caribou Biosciences, Inc. do?

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

CRBU logo
CRBU
Caribou Biosciences, Inc.
$1.8

Steven B. Kanner insider trading

Caribou Biosciences, Inc.

Dr. Steven B. Kanner has made only one insider trade between 2021-2024, according to the Form 4 filled with the SEC.

As of 6 Feb 2024 he still owns at least 302,059 units of CRBU stock.

Transaction Date Security Shares Price per share Total value Source
Option
Option to purchase Common Stock 30,577 $2.69 $82,252
Option
Common Stock 30,577 $2.69 $82,252
Option
Option to purchase Common Stock 21,401 $2.69 $57,569
Option
Common Stock 21,401 $2.69 $57,569
Option
Option to purchase Common Stock 43,248 $2.69 $116,337
Option
Common Stock 43,248 $2.69 $116,337
Sale
Common Stock 43,248 $11.22 $485,243
Option
Option to purchase Common Stock 68,306 $1.81 $123,634
Option
Option to purchase Common Stock 6,114 $2.69 $16,447
Option
Common Stock 68,306 $1.81 $123,634
Option
Common Stock 6,114 $2.69 $16,447
Option
Option to purchase Common Stock 1,549 $4.11 $6,366
Option
Common Stock 1,549 $4.11 $6,366
Option
Common Stock 9,171 $2.69 $24,670
Option
Option to purchase Common Stock 9,171 $2.69 $24,670
Purchase
Common Stock 114,860 $2.1 $241,551

Caribou Biosciences key executives

Caribou Biosciences, Inc. executives and other stock owners filed with the SEC: